June 13, 2016. By Lisette Hilton. Dermatology Times. http://dermatologytimes.modernmedicine.com/dermatology-times/news/topical-inhibits-sebum-control-acne?page=0,1
DRM01 (Dermira) had positive results in a phase 2a safety and efficacy trial and, more recently, in a phase 2b study looking at dosing of the topical for patients with facial acne vulgaris. “What’s interesting about this drug, in particular, is that this topical treatment for acne works by a unique mechanism of action in that it’s a topical therapy that reduces production of sebum. Excess sebum is one of the elements in the pathogenesis of acne. And this is something that we haven’t been able to control with topical treatments” only with oral treatments for acne, says phase 2b trial investigator Linda Stein Gold, M.D., director of dermatology clinical research and head of dermatology at Henry Ford Hospital, Detroit, Mich. DRM01 is designed to inhibit acetyl coenzyme-A carboxylase, an enzyme involved in sebum synthesis, according to Dr. Stein Gold. Dermira plans to start a phase 3 program in the first half of 2017, subject to an end-of-phase 2 meeting with the U.S. Food and Drug Administration (FDA), according to a Dermira press release. Dr. Stein Gold says that she thinks that, if approved, the topical would be appropriate for most types of acne patients, except with nodular and cystic acne.